Aims: Catheter ablation for atrial fibrillation (AF) is associated with a transitory increase in the risk of both thromboembolic and bleeding events. Evidence on the use of nonvitamin K antagonist oral anticoagulants (NOACs) in patients undergoing AF ablation mostly comes from small observational studies, underpowered to detect differences in clinical outcomes between NOACs and vitamin K antagonists (VKAs) treated patients. This updated meta-analysis aimed to determine the safety and efficacy of periprocedural anticoagulation with NOACs compared with VKAs in AF patients undergoing catheter ablation.
Summary
Aims: Catheter ablation for atrial fibrillation (AF) is associated with a transitory increase in the risk of both thromboembolic and bleeding events. Evidence on the use of nonvitamin K antagonist oral anticoagulants (NOACs) in patients undergoing AF ablation mostly comes from small observational studies, underpowered to detect differences in clinical outcomes between NOACs and vitamin K antagonists (VKAs) treated patients. This updated meta-analysis aimed to determine the safety and efficacy of periprocedural anticoagulation with NOACs compared with VKAs in AF patients undergoing catheter ablation.
Methods:
We searched MEDLINE, Cochrane library, and web sources for randomized and observational studies comparing periprocedural treatment with NOACs and VKAs in patients undergoing AF ablation. The primary safety endpoint was major bleeding events, and the primary efficacy endpoint was thromboembolic events (a composite of systemic thromboembolism, transient ischemic attack, and stroke).
Results: A total of 29 studies with 12 644 patients were included in the meta-analysis.
Overall, patients on NOACs had a significantly lower risk of major bleeding compared to VKAs either in observational studies (Peto OR 0.68; 95% CI: 0.48-0.95; P = 0.022; I 2 = 20%) or in RCTs (Peto OR 0.30; 95% CI: 0.14-0.62; P = 0.001; I 2 = 28%).
Uninterrupted NOACs reduced the risk of major bleeding when compared to uninterrupted VKAs (Peto OR 0.66; 95% CI: 0.45-0.96; P = 0.028; I 2 = 1%), similarly, interrupted NOACs lowered the risk of major bleeding compared to interrupted VKAs (Peto OR 0.29; 95% CI: 0.13-0.66; P = 0.003; I 2 = 0%; P interaction = 0.076). The rate of thromboembolic complications was very low and did not significantly differ between the study groups either in observational studies (Peto OR 0.91; 95% CI: 0.49-1.67; P = 0.755; I 2 = 0%) or in RCTs (Peto OR 0.14; 95% CI: 0.01-1.30; P = 0.083; I 2 = 0%).
Conclusions:
Use of NOACs compared to VKAs significantly reduced the risk of bleeding in patients with AF ablation. Similarly, the risk of bleeding was lower with uninterrupted NOACs than with uninterrupted VKAs, and with interrupted NOACs
| INTRODUC TI ON
Catheter ablation has become increasingly common for the treatment of symptomatic patients with atrial fibrillation (AF) refractory to pharmacological therapy. 1 Although generally well tolerated by patients, this procedure is not void of risks. In fact, catheter ablation is associated with a transitory increase in the risk of periprocedural thromboembolic and bleeding events. 1 analysis excluded the anticoagulant edoxaban. We used the main key words "atrial fibrillation" and "catheter ablation" and "dabigatran" OR "apixaban" OR "rivaroxaban" and "warfarin" OR "VKA" for our than with interrupted VKAs. The rate of thromboembolic complications was extremely low in both study groups without any differences. 
| Endpoints definition
The primary safety endpoint was major bleeding events, and the primary efficacy endpoint was thromboembolic events, consisting in a composite of systemic thromboembolism, transient ischemic attack, or stroke. The secondary endpoints were overall and minor bleeding events.
The definition of major and minor bleeding events was developed by individual studies included in the present analysis.
| Statistical analysis
Peto odds ratio (Peto OR) with 95% confidence intervals (CI) was reported to assess the primary safety and efficacy outcomes considering rare event probability estimation. The secondary outcomes were reported as risk ratios (RRs) with 95% CI. The heterogeneity among trials was assessed with the Cochrane Q test and I 2 statistical, and P < 0.1 for Q test and I 2 ≥ 50% were considered indicative of significant heterogeneity. The random-effects model using the DerSimonian-Laird method was conducted if there was significant heterogeneity, whereas the fixed-effects model using the Mantel- 
| RE SULTS

| Study characteristics
A total of 2694 records were identified, of which 29 studies [5] [6] [7] [8] [9] 12, 13, met the predefined criteria and hence were included in the analysis.
The detailed search flowchart was illustrated in Figure S1 . Overall, Table S1 .
| The primary safety endpoint
Major bleeding events were rare. Patients on NOACs had a sig- Figure S2 . lower panel; P interaction = 0.076).
| The primary efficacy endpoint
A total of 47 thromboembolic events were reported in the entire study population ( Figure   S3 . lower panel; P interaction = 0.177).
| The secondary endpoints
Although the risk of overall bleeding events in NOACs-treated pa- 
| D ISCUSS I ON
This updated meta-analysis comprehensively evaluated the safety and efficacy of NOACs vs VKAs in AF patients undergoing catheter ablation. Our major findings are the following: (a) a periprocedural anticoagulation strategy with NOACs is safe and effective, (b) use of NOACs compared to VKAs reduced the risk of bleeding events, (c) the risk of bleeding was lower with uninterrupted NOAC than with uninterrupted VKAs, and with interrupted NOACs than interrupted VKAs, (d) the risk of thromboembolic complications was extremely low in both study groups without any differences.
As we could not find heterogeneity among the studies selected for this analysis, the fixed-effects method was used for all outcomes of interest except minor bleeding events in RCTs analysis.
No publication bias was identified with symmetric funnel plots and
Egger's test. Weight to interrupted VKA with regards to reducing the risk of bleeding events. 42 Therefore, we performed subgroup analyses to compare NOACs had a trend of decreased rate of thromboembolic events (0.26% vs 0.45%) and increased rate of major bleeding (1.1% vs 0.7%) when compared to interrupted NOACs. The latest AEIOU study demonstrated that the incidence of thromboembolic events or major bleeding is similar in patients with uninterrupted apixaban vs those with minimally interrupted apixaban. This might be interpreted as the existence of a significant residual pharmacological effect at the beginning of the procedure due to the omission of only one dose of apixaban before the procedure. Therefore, in the present study, it is reasonable to define uninterrupted NOACs as suspension of NOACs <24 hours before the procedure. This discrepancy needs further evaluation via large-scale randomized controlled trials comparing the efficacy and safety of different NOACs regimens in the setting.
| LI M ITATI O N S
The studies selected for this meta-analysis displayed differences in the study protocol. In addition, most of the evidence derived from retrospective observational studies. However, analyses were performed in observational studies and in RCTs separately in the current study, and almost consistent findings were identified. There were no studies to formally evaluate the safety and efficacy of different dose of NOACs, although some studies included patients taking different doses of NOACs. Furthermore, the duration of NOACs or VKAs treatment prior to catheter ablation varied among the patients. No data on other therapies for maintenance of sinus rhythm after AF ablation were available. All of the studies included in the current analysis did not report the results of recurrent AF after ablation during follow-up. Part of studies enrolled patients with repeated procedures due to recurrent AF. These potential factors might impact the incidence of recurrent AF, which is likely associated with the occurrence of ischemic stroke.
| CON CLUS IONS
Use of NOACs compared to VKAs significantly reduced the risk of bleeding in patients with AF ablation. Similarly, the risk of bleeding was lower with uninterrupted NOACs than with uninterrupted VKAs, and with interrupted NOACs than with interrupted VKAs.
The rate of thromboembolic complications was extremely low in both study groups without any differences. 
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